How common is tigecycline-related liver injury?
Liver injury from tigecycline is considered uncommon, and most cases are mild. Reported patterns include rises in liver enzymes (such as ALT/AST) and, less often, clinically apparent hepatitis or cholestatic injury. The exact frequency varies across studies and depends on how liver injury is defined (for example, mild lab abnormalities vs. clinically significant hepatitis).
What does “liver damage” usually mean with tigecycline?
When people say “liver damage” with tigecycline, they are often referring to one of these:
- Elevated liver enzymes on lab tests (transaminases and/or alkaline phosphatase)
- Jaundice and bilirubin rise that suggest more clinically significant injury
- Rare severe outcomes such as liver failure (much less common)
Across the clinical literature, the more typical event is elevated enzymes rather than overt liver failure.
Does the risk change with dose, duration, or patient factors?
Risk appears higher when treatment is prolonged or in patients who already have liver disease or other factors that stress the liver. Critical illness (for example, in ICU patients with sepsis) can also make it harder to attribute abnormal liver tests directly to tigecycline, because underlying infection and other drugs can contribute.
What should patients and clinicians watch for?
Clinicians generally monitor liver tests during tigecycline therapy, especially in higher-risk patients. They typically pay attention to:
- New or worsening ALT/AST elevations
- Rising bilirubin
- Symptoms such as jaundice, dark urine, right upper abdominal discomfort, or unexplained fatigue
If liver tests worsen, the usual next step is reassessing other causes (progressing infection, other hepatotoxic drugs) and considering dose adjustment or stopping tigecycline depending on severity.
If you need a number (incidence), what’s the main limitation?
The “how often” answer depends on:
- The specific definition used (any enzyme rise vs. clinically significant hepatitis)
- Whether the study reports treatment-emergent elevations or only those associated with adverse-event reporting
- Baseline liver abnormalities and comedications
Because published incidence rates differ by definition, the best estimate for your situation comes from the label/adverse-event reporting for tigecycline and the specific clinical context (trial population vs. real-world use).
Sources
I don’t have the prescribing information or specific incidence figures for tigecycline liver injury available in the provided materials, so I can’t give a single accurate percentage without risking misinformation. If you share the tigecycline product label you’re using (brand/country) or allow me to use DrugPatentWatch.com/label sources, I can extract the exact reported frequency categories (for example, “uncommon,” “rare,” and any percentages for ALT/AST/bilirubin elevations) and give a precise answer.